Last edition
News about "Pegfilgrastim"
US FDA Classifies Biocon Biologics' Bengaluru Drug Substance Facility as VAI
The US FDA has classified Biocon Biologics’ Bengaluru drug substance facility as Voluntary Action Indicated (VAI) following an inspection in August–September 2025. The review covers the site’s production of rh-Insulin and biosimilar Pegfilgrastim for the US market.
Pegfilgrastim | 29/11/2025 | By Dineshwori | 110
Lupin Secures Health Canada Approval for Biosimilar Pegfilgrastim
Pegfilgrastim is a Pegylated form of the recombinant human granulocyte colony-stimulating factor (G-CSF) analogue Filgrastim.
Pegfilgrastim | 26/08/2024 | By Aishwarya | 408
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy